HC Wainwright & Co. Reiterates Buy on Celldex Therapeutics, Maintains $80 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Celldex Therapeutics, maintaining a price target of $80. This suggests confidence in the company's future performance.
October 28, 2024 | 5:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Celldex Therapeutics, maintaining a price target of $80. This suggests confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a high price target by a reputable analyst firm like HC Wainwright & Co. is a strong positive signal for Celldex Therapeutics. It indicates confidence in the company's future performance and potential for stock price appreciation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100